Moreover, triplet therapy with palbociclib, taselisib, and fulvestrant has been reported to have a positive effect in patients with heavily pretreated PIK3CA-mutantER-positive (ER+)/HER2- advanced breast cancer (18). This evidence concerns the gene ERBB2 and breast cancer.